Updates are available Correction dated 2023-11-20

Article History

First Online: 4 July 2023

Change Date: 20 November 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41591-023-02718-5

Competing interests

: R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Mission Bio, Syndax, Zentalis, Ajax, Bakx, Auron, Prelude and C4 Therapeutics, for which he receives equity support; receives research support from Ajax and Abbvie; has consulted for Janssen; and has received honoraria from Astra Zeneca and Incyte for invited lectures. J.J.T. has received research support from H3 Biomedicine and patent royalties from Fate Therapeutics. P.S.V. declares no competing interests.